Skip to content
Screener

CytomX Therapeutics CTMX Q3 2025 earnings

Reported November 6, 2025 · After market close

Revenue$6.0MMiss by $1.4M
EPS-$0.09Miss by $0.04
Revenue estimate$7.3M
EPS estimate-$0.05

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$10.4M
EPS estimate-$0.09

Financials

Q3 2025

Income statement

See full
Revenue$6.0M-82.2%
Operating income-$15.8M-484%
Net income-$14.2M-348%
EPS (diluted)-$0.09-229%

Balance sheet

See full
Cash & equivalents$34.2M-15.8%
Total debt$5.6M-47.2%
Total equity$107.4M+558%
Total assets$158.3M+13.9%

Cash flow

See full
Operating cash flow-$15.5M+25.0%
Free cash flow-$15.4M+25.7%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$526.07M+471%
Enterprise value$497.48M+700%
P/E18.8×—
P/S4.6×+3.9×

Profitability

See full
Operating margin20.5%+15.2pp
Net margin24.7%—
FCF margin-63.7%-5.4pp

Returns & leverage

See full
Debt / equity0.1×—
Current ratio3.6×+2.6×

FAQ

When did CytomX Therapeutics report Q3 2025 earnings?
CytomX Therapeutics (CTMX) reported Q3 2025 earnings on November 6, 2025 after market close.
What were CytomX Therapeutics's Q3 2025 revenue and EPS?
CytomX Therapeutics reported revenue of $6.0M and eps of $-0.09 for Q3 2025.
Did CytomX Therapeutics beat estimates in Q3 2025?
Revenue missed the consensus estimate of $7.3M by $1.4M. EPS missed the consensus estimate of $-0.05 by $0.04.
How did CytomX Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 82.2% from $33.4M a year earlier.
Where can I find CytomX Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-269533) and the 10-Q periodic report (0001193125-25-269477) directly on SEC EDGAR. The filing index links above go to sec.gov.